Open AccessPBX3 hypermethylation in peripheral blood leukocytes predicts better prognosis in colorectal cancer: A propensity score analysis
Author(s) -
Sun Hongru,
Huang Hao,
Li Dapeng,
Zhang Lei,
Zhang Yuanyuan,
Xu Jing,
Liu Ying,
Liu Yupeng,
Zhao Yashuang
Publication year - 2019
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.2321
Subject(s) - colorectal cancer , hazard ratio , medicine , methylation , oncology , dna methylation , proportional hazards model , confounding , propensity score matching , cohort , cancer , peripheral blood , stage (stratigraphy) , gastroenterology , gene , confidence interval , biology , gene expression , genetics , paleontology
Objective The significance of gene methylation in peripheral blood leukocytes (PBLs) for assessing cancer prognosis is poorly understood. Our purpose is to assess the association between PBX3 methylation in PBLs and colorectal cancer (CRC) prognosis. Methods A total of 369 CRC patients were followed up for up to 10 years in this cohort study. PBL PBX3 methylation levels were determined by methylation‐sensitive high‐resolution melting. Cox regression models and Log‐rank tests were used to analyze the associations between PBX3 methylation status and CRC prognosis with a propensity score (PS) method to control confounding biases. Results In this study, we found that CRC patients with PBL PBX3 hypermethylation status had a better overall survival (OS) (hazard ratio [HR PS‐adjusted ], 0.72 [95% CI, 0.52‐1.00]; P = 0.049). Subgroup analyses showed that the beneficial effect of PBX3 hypermethylation status on CRC 10‐years OS remained significant among UICC stage III patients ([HR PS‐adjusted ], 0.60 [95% CI, 0.38 to 0.95]; P = 0.029) and colon cancer patients ([HR PS‐adjusted ], 0.49 [95% CI, 0.26 to 0.92]; P = 0.027). Conclusion PBL PBX3 hypermethylation is positively associated with better prognosis of CRC, especially for the UICC stage III CRC patients and colon cancer patients.